Author + information
- Yong Huo,
- Stephen W.L. Lee,
- Jitendra P.S. Sawhney,
- Hyo-Soo Kim,
- Rungroj Krittayaphong,
- Stuart J. Pocock,
- Vo T. Nhan,
- Chee Tang Chin,
- Jie Jiang,
- Ana Vega,
- Nobuya Hayashi and
- Tiong K. Ong
Acute coronary syndromes (ACS) are a key cause of mortality and morbidity in Asia but antithrombotic management patterns (AMPs) used and effect on outcomes is unclear.
The Long-tErm follow-uP of antithrombotIc management patterns In Acute CORonary Syndrome patients in Asia (EPICOR Asia) study is an observational study of real-life AMPs in 12 922 ACS patients surviving until hospital discharge in eight countries/regions in Asia. We describe relationships between AMPs used from ACS diagnosis (including pre-hospital) to hospital discharge and non-fatal in-hospital outcomes using data from EPICOR Asia (NCT01361386).
Most patients (56%) received ≥2 antiplatelets (AP) + anticoagulant (AC) + no glycoprotein IIb/IIIa inhibitor (GPI). This AMP plus a GPI, or ≥2 AP only, was each used in 17% of patients, with antithrombotic drug underuse (0−1 AP + 0−1 AC + no GPI) used in 9% of patients. AMP use was similar by ACS type. Relative to the reference AMP (≥2 AP + AC + no GPI), risk for myocardial infarction in-hospital increased with drug underuse (p<0.01) while risk for hemorrhagic complications was increased for ≥2 AP + AC + GPI (p<0.001) and reduced for ≥2 AP only (p<0.01) (Figure).
No association was seen between in-hospital AMP used and in-hospital cardiac ischemic complications or stroke.
EPICOR Asia shows that combination of two AP and an AC underpins real-world antithrombotic drug use in patients hospitalized for an ACS in Asia with no uniform trend for different AMPs on outcomes.
Poster Area, South Hall A1
Sunday, April 03, 2016, 9:45 a.m.-10:30 a.m.
Session Title: Clinical and Therapuetic Factors Affecting Outcome After Acute Coronary Syndromes
Abstract Category: 14. Acute Coronary Syndromes: Clinical
Presentation Number: 1169-003
- 2016 American College of Cardiology Foundation